Among these, thymidine kinase 1 (TK1) emerged as a particularly promising candidate due to its consistent overexpression across datasets and significant correlation with poor survival in stage II–III head and neck squamous cell carcinoma (HNSC) patients. Here, TK1 is linked to head and neck squamous cell carcinoma.